Ibuprofen Impairs Allosterically Peroxynitrite Isomerization by Ferric Human Serum Heme-Albumin*

Received for publication, April 20, 2009, and in revised form, September 3, 2009. Published, JBC Papers in Press, September 3, 2009, DOI 10.1074/jbc.M109.010736

Paolo Ascenzi1,2, Alessandra di Masi1,2, Massimo Coletta3, Chiara Ciaccio4, Gabriella Fanali5, Francesco P. Nicoletti6, Giulietta Smulevich1,2, and Mauro Fasano2

From the 1Department of Biology and Interdepartmental Laboratory for Electron Microscopy, University Roma Tre, I-00146 Roma, Italy, the 2National Institute for Infectious Diseases I.R.C.C.S. “Lazzaro Spallanzani,” I-00149 Roma, Italy, the 3Department of Experimental Medicine and Biochemical Sciences, University of Roma “Tor Vergata,” I-00133 Roma, Italy, the 4Interuniversity Consortium for Research on the Chemistry of Metals in Biological Systems, I-70126 Bari, Italy, the 5Department of Structural and Functional Biology and Center of Neuroscience, University of Insubria, I-21052 Busto Arzisio (VA), Italy, and the 6Department of Chemistry, University of Firenze, I-50019 Sesto Fiorentino (FI), Italy

Human serum albumin (HSA) participates in heme scavenging; in turn, heme endows HSA with myoglobin-like reactivity and spectroscopic properties. Here, the allosteric effect of ibuprofen on peroxynitrite isomerization to NO3 catalyzed by ferric human serum heme-albumin (HSA-heme-Fe(III)) is reported. Data were obtained at 22.0 °C. HSA-heme-Fe(III) catalyzes peroxynitrite isomerization in the absence and presence of CO2; the values of the second order catalytic rate constant (k on) are 4.1 × 105 and 4.5 × 105 M−1 s−1, respectively. Moreover, HSA-heme-Fe(III) prevents peroxynitrite-mediated nitration of free added L-tyrosine. The pH dependence of k on (pK a = 6.9) suggests that peroxynitrous acid reacts preferentially with the heme-Fe(III) atom, in the absence and presence of CO2. The HSA-heme-Fe(III)-catalyzed isomerization of peroxynitrite has been ascribed to the reactive pentacoordinated heme-Fe(III) atom. In the absence and presence of CO2, ibuprofen impairs dose-dependently peroxynitrite isomerization by HSA-heme-Fe(III) and facilitates the nitration of free added L-tyrosine; the value of the dissociation equilibrium constant for ibuprofen binding to HSA-heme-Fe(III) (L) ranges between 7.7 × 10−4 and 9.7 × 10−4 M. Under conditions where [ibuprofen] is >> L, the kinetics of HSA-heme-Fe(III)-catalyzed isomerization of peroxynitrite is superimposable to that obtained in the absence of HSA-heme-Fe(III) or in the presence of non-catalytic HSA-heme-Fe(III)-cyano complex and HSA. Ibuprofen binding impairs allosterically peroxynitrite isomerization by HSA-heme-Fe(III), inducing the hexacoordination of the heme-Fe(III) atom. These results represent the first evidence for peroxynitrite isomerization by HSA-heme-Fe(III), highlighting the allosteric modulation of HSA-heme-Fe(III) reactivity by heterotropic interaction(s), and outlining the role of drugs in modulating HSA functions. The present results could be relevant for the drug-dependent protective role of HSA-heme-Fe(III) in vivo.

* This work was supported in part by grants from the Ministry for Health of Italy (National Institute for Infectious Diseases I.R.C.C.S. “Lazzaro Spallanzani,” Roma, Italy, Ricerca Corrente 2008) (to P. A.) and the Italian Ministry of University and Research (COFIN 2007SFZXZ7002) (to M. C.).

** The on-line version of this article (available at http://www.jbc.org) contains supplemental Tables S1 and S2 and Figs. S1 and S2.

1 Both authors contributed equally to this work.
2 To whom correspondence should be addressed: Dept. of Biology, University Roma Tre, Viale Guglielmo Marconi 446, I-00146 Roma, Italy. Tel: 39-06-5733-3494; Fax: 39-06-5733-6321; E-mail: ascenzi@uniroma3.it.

Human serum albumin (HSA),3 the most abundant protein in plasma (reaching a blood concentration of about 7.0 × 10−4 m), is characterized by an extraordinary ligand binding capacity, providing a depot and carrier for many compounds. HSA affects the pharmacokinetics of many drugs; holds some ligands in a strained orientation, providing their metabolic modification; renders potential toxins harmless, transporting them to disposal sites; accounts for most of the antioxidant capacity of human serum; and displays (pseudo)enzymatic properties (1–14).

HSA is a single non-glycosylated all-α-chain protein constituted by 585 amino acids, containing three homologous domains (labeled I, II, and III). Each domain is made up by two separate helical subdomains (named A and B), connected by random coils. Terminal regions of sequential domains contribute to the formation of interdomain helices linking domain IB to IIA and domain IIB to IIA, respectively (Fig. 1) (2, 3, 5, 7, 11, 13–25).

The structural organization of HSA provides a variety of ligand binding sites (Fig. 1). According to Sudlow’s nomenclature, bulky heterocyclic anions bind preferentially to Sudlow’s site I (located in subdomain IIA), whereas Sudlow’s site II (located in subdomain IIIA) is preferred by aromatic carboxylates with an extended conformation (Fig. 1). Warfarin and ibuprofen are considered as stereotype ligands for Sudlow’s site I and II, respectively (1–3, 5, 12, 14, 16, 20, 26–30).

HSA is able to bind seven equivalents of long-chain fatty acids (FAs) at multiple binding sites (labeled FA1–FA7 in Fig. 1) with different affinity (24, 31). In particular, FA1 is located within the IB subdomain, contacting the IB-IIA polypeptide linker and the long IB-IIA transdomain helix; FA2 is located at the interface between subdomains I A, IB, and IIA; FA3 and FA4 together contribute to Sudlow’s site II (i.e. the ibuprofen site in subdomain IIIA); FA5 is located within subdomain IIB with the ligand polar head oriented toward subdomain IIIA; FA6 is at the interface between subdomains IIA and IIB; FA7 corresponds to Sudlow’s site I (i.e. the warfarin binding site in subdomain IIA). FA2 and FA6 clefs appear to be the secondary binding sites of ibuprofen (1, 3, 12, 14, 16, 18–20, 32–35).

The abbreviations used are: HSA, human serum albumin; FA, fatty acid; Hb, hemoglobin; HSA-heme, human serum heme-albumin; HSA-heme-Fe(III)-CN, HSA-heme-Fe(III)-cyano complex; HSA-heme-Fe(III)-NO, ferrous nitrosylated HSA; HSA-heme-Fe(III), ferric HSA-heme; Mb, myoglobin; HPLC, high pressure liquid chromatography.
Peroxynitrite Isomerization by Ferric Heme-Albumin

Here, ibuprofen, the prototype ligand of Sudlow’s site II (1, 3, 26, 58), is reported to impair peroxynitrite\(^4\) isomerization to \(\text{NO}_3\) by HSA-heme-Fe(III), in the absence and presence of \(\text{CO}_2\). In the absence of ibuprofen, the pentacoordinated HSA-heme-Fe(III) form catalyzes peroxynitrite isomerization to \(\text{NO}_3\), preventing the nitration of free added \(\text{L-tyrosine}\). In contrast, ibuprofen induces hexacoordination of the heme-Fe(III) atom of HSA-heme-Fe(III), impairing allosterically peroxynitrite isomerization by HSA-heme-Fe(III) and allowing the nitration of free added \(\text{L-tyrosine}\). These results represent the first evidence for a drug-dependent peroxynitrite scavenging by HSA-heme-Fe(III), a condition possibly occurring in patients with various hemolytic diseases (59).

EXPERIMENTAL PROCEDURES

Materials

Hemin (Fe(III)-protoporphyrin IX) chloride was purchased from Sigma. The heme stock solution (\(5.0 \times 10^{-3} \text{ M}\)) was prepared by dissolving heme-Fe(III) in 1.0 \(\text{M}\) \(\text{NaOH}\) (60). The heme-Fe(III) concentration was determined spectrophotometrically at 535 nm, after converting heme-Fe(III) to the heme-Fe(III)-bisimidazolate derivative by adding 1.0 \(\text{m}\) imidazole, in SDS micelles (\(e_{535} = 14.5 \times 10^{3} \text{ M}^{-1}\text{cm}^{-1}\)) (61).

HSA (\(\approx 96\%\), essentially fatty acid-free) was obtained from Sigma. To remove hydrophobic ligands, HSA was dissolved in water, acidified to pH 3.5 with acetic acid, and treated for 2 h with activated charcoal at room temperature. After charcoal removal by centrifugation, the pH was brought to 7.0 with aqueous ammonia (62). The HSA concentration was determined spectrophotometrically at 280 nm (\(e_{280} = 38.2 \times 10^{3} \text{ M}^{-1}\text{cm}^{-1}\)) (60). The HSA stock solution (\(2.0 \times 10^{-3} \text{ M}\)) was prepared by diluting the hydrophobic ligand-free HSA solution with the 2.0 \(\times 10^{-2} \text{ M}\) sodium phosphate buffer, at pH 7.2. The HSA-heme-Fe(III) stock solution (\(2.0 \times 10^{-4} \text{ M}\)) was prepared by adding a 0.9-fold molar defect of heme-Fe(III) to the HSA-heme-Fe(III) solution (2.0 \(\times 10^{-2} \text{ M}\) sodium phosphate buffer, pH 7.2) (30, 37, 42, 44, 50, 54, 55, 60, 63).

The HSA and HSA-heme(III) stock solutions were diluted in the 2.0 \(\times 10^{-1} \text{ M}\) sodium phosphate buffer at the desired pH value (ranging between 6.2 and 8.1) and concentration (ranging between 1.0 \(\times 10^{-3}\) and 1.0 \(\times 10^{-4} \text{ M}\)). Peroxynitrite was synthesized from \(\text{K}_2\) and \(\text{NO}^+\) and from \(\text{HNO}_2\) and \(\text{H}_2\text{O}_2\) and stored in small aliquots at \(-80.0^\circ\text{C}\) (64, 65). The peroxynitrite stock solution (\(2.0 \times 10^{-3} \text{ M}\)) was diluted immediately before use with degassed 5.0 \(\times 10^{-2} \text{ M}\) \(\text{NaOH}\) to reach the desired concentration (50, 66–69). Nitrate and nitrite contaminations were in the range of 0–7% and 8–19% of the \(e_{280} = 38.2 \times 10^{3} \text{ M}^{-1}\text{cm}^{-1}\) (60).

Experiments in the presence of \(\text{CO}_2\), between pH 6.2 and 8.1, were carried out by adding to the protein solutions the required amount of a 5.0 \(\times 10^{-1} \text{ M}\) \(\text{NaHCO}_3\) solution. After the addition of

---

\(^{4}\)The recommended IUPAC nomenclature for peroxynitrite is oxoperoxonitrite (\(\text{ONOO}^-\)). The term “peroxynitrite” is used here to refer generically to both \(\text{ONOO}^-\) and its conjugate acid \(\text{ONOOH}\) (67, 70, 72).
of bicarbonate, the protein solutions were allowed to equilibrate for at least 5 min. For the experiments carried out in the absence of CO$_2$, all solutions were thoroughly degassed and kept under nitrogen or helium (50, 66 – 69).

Experiments in the presence of cyanide at pH 7.2 were carried out by adding 2.0 $\times$ 10^{-1} M cyanide to the HSA-heme(III) and peroxynitrite/ibuprofen/L-tyrosine solutions, in the absence and presence of CO$_2$. This cyanide concentration allowed to obtain more than 90% of HSA-heme-Fe(III)-cyanide complex (HSA-heme-Fe(III)-CN) (43, 52).

Ibuprofen was obtained from Sigma. The ibuprofen stock solution (1.0 $\times$ 10^{-2} M) was prepared by dissolving the drug in 2.0 $\times$ 10^{-2} M phosphate buffer at pH 7.2. The final L-tyrosine concentration was 1.0 $\times$ 10^{-4} M (67, 70).

All of the other chemicals were obtained from Sigma and Merck. All products were of analytical or reagent grade and were used without further purification.

Methods

The kinetics of peroxynitrite isomerization in the absence and presence of HSA-heme-Fe(III), HSA-heme-Fe(III)-CN, HSA, CO$_2$, ibuprofen, and L-tyrosine was recorded with the SMF-20 and SMF-400 rapid mixing stopped-flow apparatus (Bio-Logic SAS, Claix, France). The light path of the observation cuvette was 10 mm, and the dead time was 1.4 ms. The kinetics was monitored at 302 nm, the characteristic absorbance maximum of peroxynitrite (64, 65). Kinetic data were obtained in the absence and presence of CO$_2$ (final concentration, 1.2 $\times$ 10^{-2} M) and ibuprofen (final concentration, 5.0 $\times$ 10^{-5} to 1.0 $\times$ 10^{-2} M) by rapid mixing the protein solution (final concentration, 5.0 $\times$ 10^{-6} to 5.0 $\times$ 10^{-5} M) or the buffer solution (1.0 $\times$ 10^{-1} M phosphate buffer) with the peroxynitrite solution (final concentration, 2.5 $\times$ 10^{-5} to 2.5 $\times$ 10^{-4} M). The kinetics was obtained at 22.0 °C and between pH 6.2 and 8.1. (1.0 $\times$ 10^{-1} M phosphate buffer), the pH was always measured at the end of the reaction. No gaseous phase was present.

The kinetics of peroxynitrite isomerization in the absence and presence of HSA-heme-Fe(III) was analyzed in the framework of the minimum reaction Schemes 1 and 2, respectively (67, 70),

$$k_0 \quad \text{HOONO} \rightarrow \text{NOO}^- + \text{H}^+$$

**SCHEME 1**

$$k_{on} \quad \text{HSA-heme-Fe(III)} + \text{HOONO} \rightarrow \text{fast}$$

$$k'_{on} \quad \text{HSA-heme-Fe(III)-OONO} \rightarrow \text{HSA-heme-Fe(III)} + \text{NOO}^- + \text{H}^+$$

**SCHEME 2**

Values of the first-order rate constant for peroxynitrite isomerization in the presence of HSA-heme-Fe(III)-CN, HSA, and 1.0 $\times$ 10^{-1} M phosphate buffer (i.e. $k_0$ or $k'_0$ in the absence and presence of ibuprofen, respectively) and of the pseudo-first-order rate constant for HSA-heme-Fe(III)-mediated peroxynitrite isomerization (i.e. $k_{obs}$ or $k'_{obs}$ in the absence and presence of ibuprofen, respectively) have been determined, in the absence and presence of CO$_2$, between pH 6.2 and 8.1 at 22.0 °C, from the analysis of the time-dependent absorbance decrease at 302 nm, according to Equation 1 (67, 69 – 74),

$$[\text{peroxynitrite}] = [\text{peroxynitrite}] \times e^{-k \times t} \quad (\text{Eq. 1})$$

where $k$ is $k_0$ or $k_{obs}$ in the absence of ibuprofen and $k'_0$ or $k'_{obs}$ in the presence of ibuprofen.

Values of the second-order rate constant for HSA-heme-Fe(III)-mediated peroxynitrite isomerization (i.e. $k_{on}$ or $k'_{on}$ in the absence and presence of ibuprofen, respectively) have been determined, in the absence and presence of CO$_2$, between pH 6.2 and 8.1 at 22.0 °C, from the linear dependence of $k_{obs}$ or $k'_{obs}$ on the HSA-heme-Fe(III) concentration according to Equations 2 and 3 (67, 70, 71),

$$k_{obs} = k_{on} \times [\text{HSA-heme-Fe(III)}] + k_0 \quad (\text{Eq. 2})$$

$$k'_{obs} = k'_{on} \times [\text{HSA-heme-Fe(III)}] + k'_0 \quad (\text{Eq. 3})$$

The pH dependence of $k_0$ and $k_{on}$ for peroxynitrite isomerization in the absence and presence of HSA-heme-Fe(III) allows us to obtain, in the absence of ibuprofen and both in the absence and presence of CO$_2$, at 22.0 °C, the values of $pK_a$, $k_{lim(bottom)}$ and $k_{lim(top)}$ (67, 70 – 72) according to Equation 4,

$$k = ((k_{lim(top)} \times 10^{-pH})/(10^{-pH} + 10^{-pK_a})) \quad (\text{Eq. 4})$$

where $k$ is $k_0$ or $k_{on}$, and $k_{lim(top)}$ represents the top asymptotic value of $k$ under conditions where pH <= $pK_a$, and Equation 5,

$$k = (((k_{lim(top)} - k_{lim(bottom)}) \times 10^{-pH})/(10^{-pH} + 10^{-pK_a})) \quad + k_{lim(bottom)} \quad (\text{Eq. 5})$$

where $k$ is $k_0$ or $k_{on}$, and $k_{lim(top)}$ and $k_{lim(bottom)}$ represent the asymptotic values of $k$ under conditions where pH <= $pK_a$ or pH >= $pK_a$, respectively.

The value of the dissociation equilibrium constant for ibuprofen binding to HSA-heme-Fe(III) (L) was determined, at pH 7.2, from the dependence of $k'_{on}$ on the ibuprofen concentration (ranging between 5.0 $\times$ 10^{-5} and 1.0 $\times$ 10^{-2} M). The effect of ibuprofen concentration on $k'_{on}$ was analyzed according to Equation 6 (30, 51, 71),

$$k'_{on} = k'_{on(top)} - ((k'_{on(top)} \times [\text{ibuprofen}])/(L + [\text{ibuprofen}]))) \quad (\text{Eq. 6})$$

where $k'_{on(top)}$ represents the asymptotic value of $k'_{on}$ under conditions where [ibuprofen] = 0 (i.e. $k'_{on(top)}$ = $k'_{on}$).

NO$_3^-$ and NO$_2^-$ analysis was carried out spectrophotometrically at 543 nm by using the Griess reagent and VCl3 to catalyze the conversion of NO$_3^-$ to NO$_2^-$, as described previously (70, 75, 76). Calibration curves were obtained by measuring 4 – 8 standard sodium nitrite and sodium nitrate solutions in 1.0 $\times$ 10^{-1} M.
phosphate buffer, pH 7.2, and 22.0 °C. The samples were prepared by mixing 500 μl of a HSA-heme-Fe(III) solution (initial concentration, 1.0 × 10^{-4} M) in 2.0 × 10^{-3} M phosphate buffer, pH 7.2) with 500 μl of a peroxynitrite solution (initial concentration, 4.0 × 10^{-4} M in 1.0 × 10^{-2} M NaOH) while vortexing, at 22.0 °C, in the absence and presence of CO2 (1.2 × 10^{-3} M) and ibuprofen (2.5 × 10^{-3} M). The reaction mixture was analyzed within ~10 min. At least four separate experiments were carried out.

The reaction of peroxynitrite with free L-tyrosine was carried out at pH 7.2 and 22.0 °C by adding 0.2 ml of an alkaline (1.0 × 10^{-2} M NaOH) ice-cooled solution of peroxynitrite (2.0 × 10^{-3} M) to 1.8 ml of a buffered (1.0 × 10^{-2} M phosphate buffer, pH 7.2) ibuprofen (2.5 × 10^{-3} M) solution with 1.0-cm path length, at 22.0 °C. Small aliquots of the 1.2 × 10^{-2} M heme-Fe(III) and 1.0 × 10^{-3} M HSA solutions were diluted in the optical cell in 1.0 × 10^{-1} M phosphate buffer, 10% DMSO, pH 7.0, to a final HSA-heme-Fe(III) concentration of 1.0 × 10^{-5} M. Then small aliquots of the 1.0 × 10^{-3} M ibuprofen solution were added to the HSA-heme-Fe(III) solution, and the absorbance spectra were recorded after incubation for a few minutes after each addition. Ibuprofen binding to HSA-heme-Fe(III) was analyzed by plotting the Soret band absorbance change (ΔA) as a function of the ibuprofen concentration. Data were analyzed according to Equation 8 (30, 51, 71),

\[
\Delta A = \Delta A_{\text{max}} \times \frac{[\text{ibuprofen}]}{(L + [\text{ibuprofen}]})
\]

where \(\Delta A_{\text{max}}\) is the absorbance change at saturating ibuprofen concentration.

Kinetic and thermodynamic data were analyzed using the MatLab program (The Math Works Inc., Natick, MA). The results are given as mean values of at least four experiments ± S.D.

**RESULTS**

**HSA-Heme(III) Catalyzes Peroxynitrite Isomerization**—The kinetics of peroxynitrite isomerization, both in the absence and presence of HSA-heme-Fe(III), HSA-heme-Fe(III)-CN, HSA, and CO2, was recorded by a single-wavelength stopped-flow apparatus. Under all of the experimental conditions, a decrease of the absorbance at 302 nm was observed, as previously reported (67, 69, 70, 72–74). The kinetics of peroxynitrite isomerization was fitted to a single-exponential decay for more than 97% of its course (supplemental Fig. S1). According to the literature (67, 70), this indicates that no intermediate species (e.g. HSA-heme-Fe(III)-OONO; see Scheme 2) accumulate(s) in the course of peroxynitrite isomerization. In particular, the formation of the transient HSA-heme-Fe(III)-OONO species represents the rate-limiting step in catalysis, the conversion of the HSA-heme-Fe(III)-OONO complex to HSA-heme-Fe(III) and NO2- being faster by at least 1 order of magnitude.

In the absence of CO2, the observed rate constant for HSA-heme-Fe(III)-catalyzed isomerization of peroxynitrite (\(k_{\text{obs}}\)) increases linearly with the HSA-heme-Fe(III) concentration over the whole pH range explored (Fig. 2A). The analysis of data reported in Fig. 2A, according to Equation 2, allowed the determination of values of the first-order rate constant for peroxynitrite isomerization in the absence of HSA-heme-Fe(III) (\(k_0\), corresponding to the y intercept of the linear plots) and of the second-order rate constant for peroxynitrite isomerization by HSA-heme-Fe(III) (\(k_{\text{on}}\); corresponding to the slope of the linear plots). Values of \(k_0\) for peroxynitrite isomerization in the absence of HSA-heme-Fe(III) (Table 1) are in good agreement with those obtained in the presence of HSA-heme-Fe(III)-CN and HSA (Fig. 2B) and reported in the literature (67, 70, 72, 74).

Because of the physiological relevance attributed to the reaction between CO2 and peroxynitrite (79, 74, 77–79), the effect of the physiological concentration of CO2 on peroxynitrite isomerization by HSA-heme-Fe(III), HSA-heme-Fe(III)-CN,
Peroxynitrite Isomerization by Ferric Heme-Albumin

**TABLE 1**

<table>
<thead>
<tr>
<th>pH</th>
<th>Without CO₂</th>
<th>With CO₂</th>
<th>Without CO₂</th>
<th>With CO₂</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>k₀ (1 s⁻¹)</td>
<td></td>
<td>k₀ (1 s⁻¹)</td>
<td></td>
</tr>
<tr>
<td>6.2</td>
<td>0.67</td>
<td>3.9</td>
<td>1.1 x 10⁵</td>
<td>1.3 x 10⁵</td>
</tr>
<tr>
<td>6.4</td>
<td>0.64</td>
<td>6.2</td>
<td>9.8 x 10⁴</td>
<td>9.6 x 10⁴</td>
</tr>
<tr>
<td>6.7</td>
<td>0.43</td>
<td>8.9</td>
<td>7.9 x 10⁴</td>
<td>8.1 x 10⁴</td>
</tr>
<tr>
<td>6.9</td>
<td>0.35</td>
<td>11.9</td>
<td>6.7 x 10⁴</td>
<td>6.4 x 10⁴</td>
</tr>
<tr>
<td>7.2</td>
<td>0.28</td>
<td>17.4</td>
<td>4.1 x 10⁴</td>
<td>4.5 x 10⁴</td>
</tr>
<tr>
<td>7.5</td>
<td>0.11</td>
<td>25.3</td>
<td>2.3 x 10⁵</td>
<td>2.2 x 10⁵</td>
</tr>
<tr>
<td>7.8</td>
<td>0.086</td>
<td>32.9</td>
<td>1.3 x 10⁵</td>
<td>1.5 x 10⁵</td>
</tr>
<tr>
<td>8.1</td>
<td>0.046</td>
<td>43.7</td>
<td>6.8 x 10⁴</td>
<td>8.2 x 10⁴</td>
</tr>
</tbody>
</table>

**FIGURE 2.** Dependence of the (pseudo-)first-order rate constant for peroxynitrite isomerization on the HSA-heme-Fe(III) (k₀, A and C), HSA-heme-Fe(III)-CN (k₁, B and D), and HSA (k₂, B and D) concentration, in the absence (A and B) and presence (C and D) of CO₂ at 22.0 °C. The peroxynitrite concentration was 2.5 x 10⁻⁵ M. The CO₂ concentration was 1.2 x 10⁻⁴ M. The continuous lines in A and C were calculated according to Equation 2 with values of k₀ and k₁, given in Table 1. Where not shown, the S.D. value is smaller than the symbol in A and C. For clarity, the S.D. is shown for two k₀ values in B and D.

and HSA has been investigated. As shown in Fig. 2C, HSA-heme-Fe(III) catalyzes the isomerization of peroxynitrite in a concentration-dependent linear fashion. The analysis of data reported in Fig. 2C, according to Equation 2, allowed the determination of values of the first-order rate constant for peroxynitrite isomerization in the absence of HSA-heme-Fe(III) (kᵢ₀, corresponding to the y intercept of the linear plots) and of the second-order rate constant for peroxynitrite isomerization by HSA-heme-Fe(III) (kᵢ₁, corresponding to the slope of the linear plots). In the presence of CO₂, values of kᵢ₁ for peroxynitrite isomerization in the absence of HSA-heme-Fe(III) (Table 1) are in good agreement with those obtained in the presence of HSA-heme-Fe(III)-CN and HSA (Fig. 2D) and reported in the literature (67, 70, 74).

Values of kᵢ₀ for HSA-heme-Fe(III)-catalyzed isomerization of peroxynitrite are essentially unaffected by CO₂ (Table 1). In contrast, values of k₀ for peroxynitrite isomerization obtained in the presence of HSA-heme-Fe(III)-CN, HSA, and CO₂ are 10–100 times higher than those obtained in the absence of CO₂ (Table 1). The lack of a CO₂-linked effect on peroxynitrite isomerization by HSA-heme-Fe(III) is probably related to the fact that peroxynitrite reacts faster with HSA-heme-Fe(III) (k₀ = 4.1 x 10⁵ and 4.5 x 10⁵ M⁻¹ s⁻¹, in the absence and presence of CO₂, respectively) (Table 1) than with CO₂ (the second-order rate constant being 3 x 10⁴ M⁻¹ s⁻¹) (74, 79).

To confirm the catalytic effect of HSA-heme-Fe(III) on peroxynitrite isomerization, the dependence of k₀ and k₁ on the peroxynitrite concentration was determined in the absence and presence of HSA-heme-Fe(III), HSA-heme-Fe(III)-CN, HSA, and CO₂ concentration, at pH 6.2 (data not shown), 7.2 (Fig. 3), and 8.1 (data not shown). Under all the experimental conditions, values of k₀ and k₁ for peroxynitrite isomerization slightly decrease upon increasing peroxynitrite concentration. In contrast, the amplitude of the kinetics increases as a function of the peroxynitrite concentration (data not shown). The decrease of k₀ and k₁ values upon increasing peroxynitrite concentration at fixed HSA-heme-Fe(III) concentration in the absence and presence of CO₂ (Fig. 3) is reminiscent of what has been reported for peroxynitrite isomerization by human HbFe(III) and horse heart Mb-Fe(III) (70). This behavior has been proposed to reflect the occurrence of the peroxynitrite/peroxynitrous acid adduct at [peroxynitrite] > 5.0 x 10⁻⁵ M, around neutrality (70). Accordingly, the decrease of k₀ and k₁ values upon increasing the peroxynitrite concentration may reflect the slow HSA-heme-Fe(III)-mediated decomposition of the peroxynitrite/peroxynitrous acid adduct or the slow dissociation of the peroxynitrite/peroxynitrous acid adduct preceding HSA-heme-Fe(III)-catalyzed peroxynitrite isomerization.

To highlight the role of the heme-Fe(III) atom to catalyze peroxynitrite isomerization, the effect of HSA-heme-Fe(III)-CN and HSA concentration on the isomerization of peroxynitrite was investigated in the absence and presence of CO₂. As shown in Fig. 2, B and D, HSA-heme-Fe(III)-CN and HSA do not affect the peroxynitrite isomerization kinetics. Therefore,
Peroxy nitrite Isomerization by Ferric Heme-Albumin

FIGURE 3. Effect of peroxynitrite concentration on values of the (pseudo-)first-order rate constant for peroxynitrite isomerization in the presence of HSA-heme-Fe(III) (k_{obs} A and C), HSA-heme-Fe(III)-CN (k_{obs} B and D), and HSA (k_{obs} B and D) in the absence (A and B) or presence (C and D) of CO_2 at pH 7.2 and 22.0 °C. The HSA-heme-Fe(III), HSA-heme-Fe(III)-CN, and HSA concentrations were 5.0 × 10^{-6} M. The CO_2 concentration was 1.2 × 10^{-3} M. For clarity, the S.D. value was shown for prototypical k_{obs} values in each panel.

The acceleration of the peroxynitrite isomerization rate by HSA-heme-Fe(III) could be due to the reaction of peroxynitrite with the heme-Fe(III) atom, as reported for human Hb-Fe(III) and horse heart Mb-Fe(III) (70).

The pH dependence of k_{0} and k_{on} for peroxynitrite isomerization, in the absence and presence of HSA-heme-Fe(III) and CO_2, was examined to identify tentatively the species that preferentially react(s) with HSA-heme-Fe(III). Values of k_{0} and k_{on} shown in Fig. 4 were derived from data reported in Fig. 2, A and C, and are listed in Table 1. Values of k_{0} for peroxynitrite isomerization in the absence of HSA-heme-Fe(III) but in the presence of CO_2 decrease upon increasing pH from 6.2 to 8.1 (Fig. 4A). In contrast, values of k_{0} for peroxynitrite isomerization in the absence of HSA-heme-Fe(III) and CO_2 (pK_a = 6.8) (Fig. 4B) could indicate that the species undergoing the isomerization is a transient highly reactive intermediate(s) formed by the reaction of peroxynitrite with CO_2. Since peroxynitrite has been reported to react with CO_2, leading to the formation of an adduct whose composition is believed to be NOOC(O)(O)^{−} (named 1-carboxylato-2-nitrosodioxidane) (74, 79), this might be the transient species that then converts to NO_3 and CO_2 either directly or by transient formation of trioxocarbonate(1−) (CO_3^2−) and NO_2. On the other hand, the similar pK_a values for peroxynitrite isomerization by HSA-heme-Fe(III), both in the absence and in the presence of CO_2 (pK_a = 6.9), indicates that peroxynitrite reacts with HSA-heme-Fe(III) as HOONO.

Ibuprofen Impairs HSA-Heme-Fe(III)-mediated Isomerization of Peroxy nitrite—In the absence and presence of CO_2, ibuprofen impairs dose-dependently HSA-heme-Fe(III)-mediated isomerization of peroxynitrite (Fig. 5). Mixing HSA-heme-Fe(III) with peroxynitrite, in the presence of ibuprofen and in the absence and presence of CO_2, brings about a decrease of the absorbance at 302 nm (supplemental Fig. S2, A and B). Moreover, the kinetics of peroxynitrite isomerization by HSA-heme-Fe(III), in the presence of ibuprofen and in the absence and presence of CO_2, was fitted to a single-exponential decay for more than 97% of its course (supplemental Fig. S2, A and B). These findings agree with the results concerning peroxynitrite isomerization in the absence of ibuprofen (see above and supplemental Fig. S1).

The observed rate constant for HSA-heme-Fe(III)-catalyzed isomerization of peroxynitrite (k'_{obs}) increases linearly with the HSA-heme-Fe(III) concentration over the whole ibuprofen concentration range explored, in the absence and presence of CO_2 and in the absence of HSA-heme-Fe(III) (pK_a = 7.6) (Fig. 4B) could indicate that the species undergoing the isomerization is a transient highly reactive intermediate(s) formed by the reaction of peroxynitrite with CO_2. Since peroxynitrite has been reported to react with CO_2, leading to the formation of an adduct whose composition is believed to be NOOC(O)(O)^{−} (named 1-carboxylato-2-nitrosodioxidane) (74, 79), this might be the transient species that then converts to NO_3 and CO_2 either directly or by transient formation of trioxocarbonate(1−) (CO_3^2−) and NO_2. On the other hand, the similar pK_a values for peroxynitrite isomerization by HSA-heme-Fe(III), both in the absence and in the presence of CO_2 (pK_a = 6.9), indicates that peroxynitrite reacts with HSA-heme-Fe(III) as HOONO.
CO\textsubscript{2}. The analysis of data reported in Fig. 5, A and B, according to Equation 3, allowed the determination of values of the first-order rate constant for peroxynitrite isomerization in the absence of HSA-heme-Fe(III) (\(k_0\)); corresponding to the y intercept of the linear plots) and of the second-order rate constant for peroxynitrite isomerization by HSA-heme(III) (\(k_{on}\); corresponding to the slope of the linear plots) in the presence of ibuprofen and in the absence and presence of CO\textsubscript{2}. As shown in Table 2, CO\textsubscript{2} does not affect \(k_{on}\) values but alters \(k_0\) values.

The effect of ibuprofen concentration on \(k_{on}\) values for HSA-heme-Fe(III)-mediated isomerization of peroxynitrite is shown in Fig. 5C. Values of \(k_0\) and \(k_{on}\) shown in Fig. 5C were derived from data reported in Fig. 5, A and B, and are listed in Table 2. Values of \(k_0\) are unaffected by ibuprofen concentration.
The analysis of the dependence of the relative yield of nitro-L-tyrosine against peroxynitrite-mediated nitration. The relative yield of nitro-L-tyrosine increased upon increasing the ibuprofen concentration, at fixed HSA-heme-Fe(III), peroxynitrite isomerization prompted us to analyze the data, according to Equation 7, allowed the determination of values of the dissociation equilibrium constant \( L \) in the absence and presence of CO\(_2\) (8.7 \( \times \) 10\(^{-4}\) M, respectively). Relative yield (%) = (yield with added protein/yield with no protein) \( \times \) 100. Where not shown, the S.D. value is smaller than the symbol.

### Peroxynitrite Isomerization by Ferric Heme-Albumin

**FIGURE 6.** Effect of HSA-heme-Fe(III), HSA-heme-Fe(III)-CN, and HSA concentration on the relative yield of nitro-L-tyrosine formed from the reaction of peroxynitrite with free L-tyrosine, at pH 7.2 and 22.0 °C, in the absence and presence of CO\(_2\). The free L-tyrosine concentration was 1.0 \( \times \) 10\(^{-4}\) M. The peroxynitrite and CO\(_2\) concentration was 2.0 \( \times \) 10\(^{-4}\) and 1.2 \( \times \) 10\(^{-3}\) M, respectively.

### Table 2

Effect of the ibuprofen concentration on \( k'_i \) and \( k''_i \) values for HSA-heme-Fe(III)-mediated peroxynitrite isomerization in the absence and presence of CO\(_2\), at pH 7.2 and 22.0 °C

<table>
<thead>
<tr>
<th>Ibuprofen</th>
<th>( k'_i ) Without CO(_2)</th>
<th>With CO(_2)</th>
<th>( k''_i ) Without CO(_2)</th>
<th>With CO(_2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0 ( \times ) 10(^{-5})</td>
<td>0.26 ( \times ) 10(^{-5})</td>
<td>17.8 ( \times ) 10(^{-5})</td>
<td>4.1 ( \times ) 10(^{-5})</td>
<td>4.5 ( \times ) 10(^{-5})</td>
</tr>
<tr>
<td>5.0 ( \times ) 10(^{-5})</td>
<td>ND</td>
<td>19.3</td>
<td>4.1 ( \times ) 10(^{-5})</td>
<td></td>
</tr>
<tr>
<td>1.0 ( \times ) 10(^{-4})</td>
<td>0.23</td>
<td>3.9 ( \times ) 10(^{-5})</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>2.0 ( \times ) 10(^{-4})</td>
<td>0.28</td>
<td>18.1</td>
<td>3.5 ( \times ) 10(^{-5})</td>
<td></td>
</tr>
<tr>
<td>4.0 ( \times ) 10(^{-4})</td>
<td>0.25</td>
<td>17.6</td>
<td>2.9 ( \times ) 10(^{-5})</td>
<td></td>
</tr>
<tr>
<td>8.0 ( \times ) 10(^{-4})</td>
<td>0.22</td>
<td>2.4 ( \times ) 10(^{-5})</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>1.0 ( \times ) 10(^{-3})</td>
<td>0.24</td>
<td>18.4</td>
<td>2.2 ( \times ) 10(^{-5})</td>
<td></td>
</tr>
<tr>
<td>1.6 ( \times ) 10(^{-3})</td>
<td>ND</td>
<td>19.0</td>
<td>1.7 ( \times ) 10(^{-5})</td>
<td></td>
</tr>
<tr>
<td>2.0 ( \times ) 10(^{-3})</td>
<td>0.26</td>
<td>1.5 ( \times ) 10(^{-5})</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>2.5 ( \times ) 10(^{-3})</td>
<td>0.25</td>
<td>18.4</td>
<td>1.1 ( \times ) 10(^{-5})</td>
<td></td>
</tr>
<tr>
<td>4.0 ( \times ) 10(^{-3})</td>
<td>ND</td>
<td>16.9</td>
<td>9.0 ( \times ) 10(^{-5})</td>
<td></td>
</tr>
<tr>
<td>5.0 ( \times ) 10(^{-3})</td>
<td>0.27</td>
<td>7.5 ( \times ) 10(^{-5})</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>1.0 ( \times ) 10(^{-2})</td>
<td>0.22</td>
<td>3.5 ( \times ) 10(^{-5})</td>
<td>ND</td>
<td></td>
</tr>
</tbody>
</table>

*Under conditions where [ibuprofen] = 0.0 \( \times \) 10\(^{-5}\), \( k'_i = k'_i \) and \( k''_i = k''_i \).

*ND, not determined.

With CO\(_2\), the relative yield of nitro-L-tyrosine increased (\( \sim \)90%) and decreased (\( \sim \)10%), respectively, as reported for peroxynitrite isomerization catalyzed by human Hb-Fe(III) and horse heart Mb-Fe(III) (70). The same result has been observed in the presence of HSA-heme-Fe(III) and/or CO\(_2\), according to the literature (70, 80). Last, ibuprofen does not significantly affect the NO\(_3\) and NO\(_2\) yields (supplemental Table S1).

**Ibuprofen Impairs HSA-Heme-Fe(III)-based Protection of Free L-Tyrosine against Peroxynitrite-mediated Nitration**—To investigate the protective role of HSA-heme-Fe(III) against peroxynitrite-mediated nitration, the relative yield of nitro-L-tyrosine formed by the reaction of peroxynitrite with free L-tyrosine in the presence of HSA-heme-Fe(III) was determined.

As shown in Fig. 6, HSA-heme-Fe(III) protects dose-dependently free L-tyrosine against peroxynitrite-mediated nitration. In contrast, L-tyrosine nitration is not prevented by HSA-heme-Fe(III)-CN and HSA, and the relative nitro-L-tyrosine yield corresponds to that observed in the absence of HSA derivatives. According to previous results (67, 70), HSA-heme-Fe(III) was slightly less efficient at preventing peroxynitrite-mediated nitration of free L-tyrosine in the presence than in the absence of CO\(_2\).

The ability of ibuprofen to impair allosterically HSA-heme-Fe(III)-mediated peroxynitrite isomerization prompted us to investigate the role of this drug in modulating peroxynitrite-based L-tyrosine nitration, in the absence and presence of CO\(_2\). The relative yield of nitro-L-tyrosine increased upon increasing the ibuprofen concentration, at fixed HSA-heme-Fe(III), peroxynitrite, L-tyrosine, and CO\(_2\) concentration (Fig. 7).

**Supplemental Material** can be found at: http://www.jbc.org/content/suppl/2009/09/03/M109.010736.DC1.html
Peroxyxinitrite Isomerization by Ferric Heme-Albumin

FIGURE 7. Effect of ibuprofen concentration on the relative yield of nitro-L-tyrosine formed from the reaction of peroxynitrite with free L-tyrosine, at pH 7.2 and 22.0 °C, in the presence of HSA-heme-Fe(III) and in the absence (A) and presence (B) of CO2. The continuous lines were calculated according to Equation 7 with the following parameters: $L = 8.7 \times 10^{-4}$ M and $r = 21.1$% (A) and $L = 8.4 \times 10^{-5}$ M and $r = 25.9$% (B). The concentration of HSA-heme-Fe(III), peroxynitrite, free-L-tyrosine, and CO2 was 2.5 $\times 10^{-5}$, 2.0 $\times 10^{-5}$, 1.0 $\times 10^{-4}$, and 1.2 $\times 10^{-4}$ M, respectively. Relative yield (%) = (yield with added protein/yield with no protein) $\times$ 100. Where not shown, the S.D. value is smaller than the symbol.

FIGURE 8. Spectrophotometric titration of ibuprofen binding to HSA-heme-Fe(III), at pH 7.2 and 22.0 °C. The HSA-heme-Fe(III) concentration was 1.0 $\times 10^{-5}$ M. The continuous line was calculated according to Equation 8 with $L = 7.7 \times 10^{-4}$ M. Where not shown, the S.D. value is smaller than the symbol.

agreement with those obtained from the effect of ibuprofen concentration on (i) HSA-heme-Fe(III)-catalyzed isomerization of peroxynitrite in the absence and presence of CO2 ($L = 9.7 \times 10^{-4}$ M) (Fig. 5C) and (ii) the relative nitro-L-tyrosine yield in the absence and presence of CO2 ($L = 8.7 \times 10^{-4}$ and 8.4 $\times 10^{-4}$ M, respectively) (Fig. 7). Note that the heme-Fe(III)-ibuprofen complex, which could potentially interfere, only occurs at an ibuprofen concentration of $\geq 7.5 \times 10^{-2}$ (38).

DISCUSSION

Ibuprofen, the prototype ligand of Sudlow’s site II (1, 3, 26, 58), modulates allosterically peroxynitrite isomerization by HSA-heme-Fe(III) and therefore the peroxynitrite-mediated nitration of free L-tyrosine, highlighting the role of heterotropic ligands on the HSA reactivity (11, 13, 52, 81).

Peroxyxinitrite isomerization is facilitated by the HSA-heme-Fe(III) species, whereas the HSA-heme-Fe(III)-CN derivative and the heme-free HSA are both non-reactive, clearly demonstrating that the efficiency of the isomerization process mirrors the heme-Fe(III) reactivity. As already reported for horse and sperm whale Mb and human Hb (67, 70), peroxyxinitrous acid appears to be the species that preferentially reacts with HSA-heme-Fe(III). In addition, like horse heart Mb, sperm whale Mb, and human Hb (67, 70), HSA-heme-Fe(III) protects free L-tyrosine from peroxyxinitrite-mediated nitration.

Allosteric inhibition of the HSA-heme-Fe(III)-mediated peroxyxinitrite isomerization by ibuprofen is related to drug-dependent structural changes occurring at the FA1 site (i.e. at the heme binding pocket). Indeed, UV-visible, resonance Raman, and electron paramagnetic resonance spectroscopies evidenced that the pentacoordinated heme-Fe(III) atom of HSA-heme-Fe(III), observed in the absence of ibuprofen, becomes hexacoordinated low spin upon ibuprofen binding (38). On the basis of the crystal structure of HSA-heme-Fe(III) (21), the His$^{146}$ residue was suggested as the putative ligand able to coordinate to the heme-Fe(III) atom in the sixth position upon ibuprofen binding (38). In contrast, in both ibuprofen-free pentacoordinated and ibuprofen-bound hexacoordinated HSA-heme-Fe(III), the Tyr$^{161}$ residue coordinates to the heme-Fe(III) atom in the fifth position (38). Therefore, the presence of a strong ligand (either the His$^{146}$ residue or the exogenous cyanide ligand) at the sixth coordination position of the heme-Fe(III) atom inhibits peroxyxinitrite isomerization, thus rendering HSA-heme-Fe(III) non-reactive.

The identity of the ibuprofen binding pocket(s) (among the three possible ones, namely FA2, FA6, and Sudlow’s site II) responsible for this allosteric effect is still unclear.

Structural and solution studies of ibuprofen binding to HSA have shown that the ibuprofen primary binding site (i.e. Sudlow’s site II formed by FA3 and FA4 clefts) does not appear to be allosterically linked to the heme binding site (i.e. FA1) (30, 37, 38, 55), ruling out the possibility that Sudlow’s site II is responsible for the effect of ibuprofen on peroxyxinitrite isomerization by HSA-heme-Fe(III).

An additional candidate might be the ibuprofen secondary site FA6, which modulates negatively heme-Fe(III) binding to FA1 (12, 37) and the affinity of the secondary drug binding cleft FA2 (34, 37, 38, 81). The FA6 site (located within domain IIA at the interface between subdomains IIA and IIB)
is in close structural and functional contact with Sudlow’s site I (i.e. the warfarin binding site), which is allosterically linked to the heme binding cleft (i.e. FA1) (12, 37). However, since the dissociation equilibrium constant for ibuprofen binding to the FA6 site has been reported to fall in the $10^{-7}$ to $1.3 \times 10^{-3}$ M range (depending on the presence and absence of allosteric effector(s)) (55), we can also rule out that the effect of ibuprofen on peroxynitrite isomerization is related to drug binding to the FA6 site. Indeed, the average value of the dissociation equilibrium constant for ibuprofen binding to HSA–heme–Fe(III) here determined ($L$) from the dependence of either $k_{on}$ or the relative yield of nitro-L-tyrosine or spectrophotometric changes in the Soret band on the ibuprofen concentration is at least 50-fold higher ($8.8 \times 10^{-4}$ M) (Figs. 6–8).

As a whole, FA2, the only ligand binding site that provides contacts with different HSA subdomains (being located at the interface between subdomains IIA and IIB), could represent the ibuprofen secondary cleft functionally linked to the heme–Fe(III) atom reactivity (37). Thus, the average value of $L$ ($8.8 \times 10^{-4}$ M) here determined (Figs. 6–8) could reflect ibuprofen binding to the FA2 site of HSA–heme–Fe(III).

Noticeably, this $L$ value is grossly similar to that obtained from the ibuprofen-dependent resonance Raman spectroscopic changes of HSA–heme–Fe(III), reflecting hexacoordination of the heme–Fe(III) atom ($L = 4.0 \times 10^{-8}$ M) (38).

Peroxynitrite isomerization by heme–Fe(III) proteins (e.g. HSA–heme–Fe(III)) could represent a physiological detoxification mechanism, protecting cells from reactive nitrogen and oxygen species (78). Note that values of $k_{on}$ for peroxynitrite isomerization by HSA–heme–Fe(III) are higher by about 1 order of magnitude than those reported for ferric horse heart Mb, sperm whale Mb, human Hb, and heme-model compounds (67, 70, 82, 83) (supplemental Table S2). Moreover, peroxynitrite isomerization by HSA–heme–Fe(III) (supplemental Table S2) is faster than peroxynitrite scavenging by ferrous nitrosylated heme proteins, which appears to be strongly limited by (i) the dissociation of the transient heme–Fe(III)–NO and (ii) the reduction of the final heme–Fe(III) species to the heme–Fe(II) derivative (50). Remarkably, peroxynitrite isomerization by heme–Fe(III) proteins (e.g. HSA–heme–Fe(III)) does not require any redox cycle.

Due to the relevant physiological role of HSA in human plasma, several in vivo implications can be argued from the present results. Indeed, peroxynitrite isomerization by HSA–heme–Fe(III) could occur only in patients affected with a variety of severe hematologic diseases characterized by excessive intravascular hemolysis. Under these pathological conditions, the HSA–heme–Fe(III) plasmatic level increases from the physiological concentration ($\sim 1 \times 10^{-6}$ M) to $\sim 4 \times 10^{-9}$ M (59, 84), HSA acting as the main heme–Fe(III) plasma depot (84, 85). To mimic as much as possible this condition, the HSA–heme–Fe(III) concentration here used ranged from $5.0 \times 10^{-6}$ to $5.0 \times 10^{-5}$ M. The high heme plasma concentration is invariably associated with a reduction of hemopexin in patients affected by excessive intravascular hemolysis (59). Note that upon increasing heme plasma level, hemopexin, whose plasma concentration ($\sim 1.5 \times 10^{-8}$ M) (84, 85) is about 2 orders of magnitude lower than that of HSA ($7.5 \times 10^{-4}$ M) (3), undergoes hemolysis, highlighting the role of HSA as a heme scavenger (84, 85).

Although the in vivo concentration of peroxynitrite is openly debated, the level of peroxynitrite in the reperfused ischemic heart has been reported to be much higher than micromolar concentration, at least over brief period of time (86, 87), overlapping with the lowest peroxynitrite concentration here used ($2.5 \times 10^{-5}$ M).

Finally, considering the plasma level of ibuprofen ($\sim 10^{-4}$ to $10^{-3}$ M) (88–90), the drug concentration here used ranged between $5.0 \times 10^{-5}$ M and $1.0 \times 10^{-2}$ M. Accounting for the average $L$ value ($8.8 \times 10^{-4}$ M) here determined and the plasma level of ibuprofen, the molar fraction of the drug-bound HSA–heme–Fe(III) could range between 10 and 50%.

**CONCLUSIONS**

Data here reported highlight the role of drugs in modulating HSA functions. This is relevant for the potential role played by HSA–heme in the detoxification process, also taking into account that the HSA–heme–Fe(III) plasmatic concentration increases significantly under pathological conditions (11, 13, 52, 59, 84). Therefore, the higher HSA–heme concentration and the higher efficiency of peroxynitrite isomerization altogether contribute to identify HSA–heme as a major detoxification element in the bloodstream. This aspect acquires an even higher value in consideration of the protective role, played by the peroxynitrite isomerization, on the nitration of aromatic residues (such as tyrosine), which represent a relevant post-translational protein modification process (91). Last, HSA, not only acting as a heme carrier but also displaying transient heme-based properties, represents a case for “chronosteric effects” (52), which goes heme saturation, highlighting the role of HSA as a heme scavenger (84, 85), e.g. HSA–heme–Fe(III).

**Acknowledgment**—We thank Dr. Elisabetta De Marinis for helpful discussions.

**REFERENCES**

153–164